AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal

AstraZeneca (AZN) announced positive results from the ongoing phase III EMERALD-I study, which is evaluating Imfinzi (durvalumab) as a combination therapy in hepatocellular carcinoma (HCC), the most common form of liver cancer.The EMERALD-1 study is evaluating the combination of Imfinzi combined with bevacizumab and transarterial chemoembolization (TACE), compared with TACE alone, for the treatment of unresectable HCC in patients eligible for embolization.The study achieved its primary endpoint of statistic ...